TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01538316

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin supplement
Description: 500 mg/d quercetin (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by genistein and placebo supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Genistein supplement
Description: 100 mg/d genistein (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by placebo and quercetin supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vitamin C + folic acid + vitamin B3 over a period of six months; crossover design (6 month-periods): followed by quercetin and genistein supplement.
Study: NCT03792971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan HBr
Description: A single 60 mg dose of DM capsules liquid-filled on Day 1 and Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: Daily 90 mg IV infusions over 60 minutes on Day 3 and Day 4
Study: NCT03334565

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low efficiency air filtration systems
Description: Subjects were exposed to low-efficiency filtered air.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High efficiency air filtration systems
Description: Subjects were exposed to high-efficiency filtered air.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Air filtration systems without filters (sham)
Description: Subjects were exposed to unfiltered air.
Study: NCT01223196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: This study will examine the effect of Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo for comparison to Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
Study: NCT01653483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719
Description: Novel Dry-Powder Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719matched-placebo
Description: Novel Dry-Powder Inhaler
Study: NCT02629133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHE Program
Description: The SHE program is specifically tailored, innovative and relevant to diverse, racial, and ethnic sheltered, battered women in a number of ways including the images and content used in the intervention. It is also tailored to participants' alcohol or substance use status, and designed to reach participants across levels of motivation for change. The content of SHE is theory-driven, consistent with the motivational interviewing model of behavior, and consistent with the literature on effective interventions that address IPV and substance use.
Study: NCT01997528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Change of blood flow or sweep gas flow ( ILA Activve)
Study: NCT00612833

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vasectomy occlusion techniques
Description: Cautery and excision with fascial interposition Cautery and excision without fascial interposition Ligation and excision with fascial interposition

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vasectomy occlusion techniques
Description: Cautery and excision with fascial interposition Cautery and excision without fascial interposition Ligation and excision with fascial interposition
Study: NCT04667455

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker analysis at enrolment
Description: Controls will be compared to cases using blood-based biomarker analyses and non-invasive cardiac imaging techniques to improve early diagnosis and risk stratification of cases

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker analyses throughout the study
Description: Controls will be compared to cases using blood-based biomarker analyses and non-invasive cardiac imaging techniques to improve early diagnosis and risk stratification of cases
Study: NCT02860728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Resistance Training
Description: Lower body resistance exercises will be prescribed in various combinations over multiple days and individually modified and progressed to achieve advances in both movement pattern, intensity, and exercise volume.
Study: NCT04704869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryoprecipitate
Description: Cryoprecipitate is a blood product high in fibrinogen. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red Blood Cells
Description: RBCs are utilized as part of the Massive Transfusion protocol for hemorrhage control.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cells
Description: RBCs are utilized as part of the Massive Transfusion protocol for hemorrhage control.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma
Description: Plasma is utilized as part of the Massive Transfusion protocol for hemorrhage control.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasma
Description: Plasma is utilized as part of the Massive Transfusion protocol for hemorrhage control.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelets
Description: Platelets are utilized as part of the Massive Transfusion protocol for hemorrhage control.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelets
Description: Platelets are utilized as part of the Massive Transfusion protocol for hemorrhage control.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole Blood
Description: Whole Blood is utilized as part of the Massive Transfusion protocol for hemorrhage control.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Whole Blood
Description: Whole Blood is utilized as part of the Massive Transfusion protocol for hemorrhage control.
Study: NCT00612833

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vasectomy occlusion techniques
Description: Cautery and excision with fascial interposition Cautery and excision without fascial interposition Ligation and excision with fascial interposition
Study: NCT03049956

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ocular vestibular evoced myogenic potentials
Description: The oVEMP technique is an accepted standard for testing otolith function in vestibular patients. It represents a quick, simple and non-invasive technique utilizing repetitive stimulation of the otolith organs with bone-conducted vibration to elicit an extraocular muscle response. Repetitive oVEMP stimulation leads to a characteristic decrement in patients with myasthenia, which can be quantified with surface electromyography from the inferior oblique muscle underneath the eye.
Study: NCT03457025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Corticosteroids
Description: Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Corticosteroids
Description: Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antivirals
Description: acyclovir 400mg: one pill 4 times daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral antivirals
Description: acyclovir 400mg: one pill 4 times daily for 7 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 2.4atm administered for twice daily dives for 5 days, 10 dives total. To be begun in the first 1 week after onset of paralysis.
Study: NCT04482010

Intervention type: OTHER
Group type: OTHER
Intervention: Local community-based HIV care
Description: Compared to the classic HIV care, community-based HIV care includes:~* Individual interviews with a psychosocial agent;~* Support groups conducted by psychosocial agents;~* Culinary workshops gathering PLWHIV and healthcare professionals;~* Home visits by a community worker;~* Emergency relief based on a funding for patients with urgent needs~As in the classic HIV care, ARCAD Santé PLUS provides consultations with doctors, prescriptions and delivery of antiretroviral (ARV) treatment every 3 months, biological analyses for enrolment, and follow-up every 6 months. In addition, psychosocial agents from ARCAD Santé PLUS propose workshops on education and support for adherence to treatment.
Study: NCT04146220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Patients of the low and the high dose groups recieved prednisolone in different dose for initial 4 weeks, then tapered gradually. Both groups received pulse I/V methylprednisolone 500 mg/day daily for initial 3 days and monthly cyclophosphamide infusion 750-1000 mg/m2 body surface area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Patients of the low and the high dose groups recieved prednisolone in different dose for initial 4 weeks, then tapered gradually. Both groups received pulse I/V methylprednisolone 500 mg/day daily for initial 3 days and monthly cyclophosphamide infusion 750-1000 mg/m2 body surface area.
Study: NCT01513057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 250 mg capsules of Roche Laboratories Inc.
Study: NCT02184494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)
Description: Subjects will be exposed to vertical vibration with a frequency and peak-to-peak displacement of 30 Hz and 1 mm, respectively, which provides a peak-to-peak acceleration of about 4.16 G.~Whole Body Vibration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)
Description: Subjects will be exposed to vertical vibration with a frequency and peak-to-peak displacement of 30 Hz and 1 mm, respectively, which provides a peak-to-peak acceleration of about 4.16 G.~Whole Body Vibration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)
Description: Subjects will be exposed to vertical vibration with a frequency and peak-to-peak displacement of 30 Hz and 1 mm, respectively, which provides a peak-to-peak acceleration of about 4.16 G.~Whole Body Vibration
Study: NCT01783496

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermage CPT
Description: Treatment with Thermage patterned, total, or framed tip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermage CPT
Description: Treatment with Thermage patterned, total, or framed tip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermage CPT
Description: Treatment with Thermage patterned, total, or framed tip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermage CPT
Description: Treatment with Thermage patterned, total, or framed tip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermage CPT
Description: Treatment with Thermage patterned, total, or framed tip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermage CPT
Description: Treatment with Thermage patterned, total, or framed tip
Study: NCT01691365

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamins
Description: a capsule of antioxidant vitamins 221mg of alpha tocopherol and 167mg of vitamin C and B-group vitamins (1.67 mg folic acid, 1.67mg vitamin B-2, 20 mg vitamin B-6, 0.134 mg vitamin B-12) or an identical placebo daily for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule shell (Hydroxypropylmethyl cellulose, Hydroxypropylcellulose, Propylene glycol as stabilizer, Colour-Titanium dioxide)
Study: NCT00048971

Intervention type: GENETIC
Intervention: mutation analysis

Intervention type: GENETIC
Intervention: polymorphic microsatellite marker analysis
Study: NCT01279642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Doppler vascular ultrasound guidance to PICC insertion in children -

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional puncture
Description: traditional approach of PICC insertion by visualization and inspection of insertion site
Study: NCT01238822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: 18 mg methylphenidate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: 36 mg methylphenidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: 54 mg methylphenidate
Study: NCT01475669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate (Human) (FCH)
Description: Single dose infused intravenously within 5 minutes of the completion of the measurement of the 5-minute bleeding mass; the dose is determined individually based on the measured maximum clot firmness (MCF) and subject body weight

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of sodium chloride solution infused intravenously within 5 minutes at a volume equivalent to that needed for FCH
Study: NCT01691755

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral doses once a day for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally once a day for 26 weeks
Study: NCT03054025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Phone Monitoring Device
Description: Use activity tracker application
Study: NCT02048397

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary Rehabilitation

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate
Study: NCT01785875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
Study: NCT04409002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1
Study: NCT02888132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided transthoracic radio frequency ablation for HOCM ventricular septum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided transthoracic laser ablation for HOCM ventricular septum
Study: NCT03058497

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temperature-Controlled Laminar Airflow Device (Airsonett®)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Temperature-Controlled Laminar Airflow Device (Airsonett®)
Study: NCT00773526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5126766
Description: Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
Study: NCT02974413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-care supported
Description: The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.The study will also include a Control Group (CG).
Study: NCT03780894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]
Description: Administration of 2 mg of FC together with RBC and TXA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red blood cells concentrate
Description: Administration of 2 red blood cells concentrates together with FC and TXA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Administration of 1g of TXA together with FC and RBC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Administration of 1g of TXA together with FC and RBC
Study: NCT00706706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate (SU011248)
Description: Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
Study: NCT04273152

Intervention type: DIAGNOSTIC_TEST
Intervention: advanced glycation endproducts reader
Description: advanced glycation endproducts reader

Intervention type: DIAGNOSTIC_TEST
Intervention: advanced glycation endproducts reader
Description: advanced glycation endproducts reader
Study: NCT03526107

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CF Control
Description: CF Control: 587 mg of cocoa flavanols, \<1 mg caffeine and \<1 mg theobromine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CF-Theobromine
Description: CF-Theobromine: 575 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CF-Caffeine
Description: CF-Caffeine: 587 mg of cocoa flavanols, 112 mg caffeine and \<1 mg theobromine
Study: NCT00661674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO
Study: NCT03097757

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound - guided fracture reduction
Description: Ultrasound will be used as a real-time imaging modality to guide forearm fracture reduction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care fracture reduction
Description: Closed reduction of a fractured bone.
Study: NCT00661674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO
Study: NCT03097757

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care fracture reduction
Description: Closed reduction of a fractured bone.
Study: NCT01159808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: 3, 25 and 100 mg capsules; oral administration, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsules, oral administration, single dose
Study: NCT04124211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: FMT will be performed through transendoscopic enteral tubing (TET) within one week during treatment period
Study: NCT04126980

Intervention type: BEHAVIORAL
Intervention: Rates of readmission and reoperation
Description: All patients were then followed-up for 180 days after the indexed surgery of lumbar fusion. All-causes of re-hospitalization and re-operations for lumbar spine fusion, were analyzed at 30, 60 and 180 days for comparison between the ED group and the comparison group.

Intervention type: BEHAVIORAL
Intervention: Rates of readmission and reoperation
Description: All patients were then followed-up for 180 days after the indexed surgery of lumbar fusion. All-causes of re-hospitalization and re-operations for lumbar spine fusion, were analyzed at 30, 60 and 180 days for comparison between the ED group and the comparison group.